CL2018001056A1 - Vacuna contra el virus herpes simplex - Google Patents
Vacuna contra el virus herpes simplexInfo
- Publication number
- CL2018001056A1 CL2018001056A1 CL2018001056A CL2018001056A CL2018001056A1 CL 2018001056 A1 CL2018001056 A1 CL 2018001056A1 CL 2018001056 A CL2018001056 A CL 2018001056A CL 2018001056 A CL2018001056 A CL 2018001056A CL 2018001056 A1 CL2018001056 A1 CL 2018001056A1
- Authority
- CL
- Chile
- Prior art keywords
- herpes simplex
- simplex virus
- virus vaccine
- vaccines
- arn
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 241000700584 Simplexvirus Species 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920002477 rna polymer Polymers 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245031P | 2015-10-22 | 2015-10-22 | |
| US201562245159P | 2015-10-22 | 2015-10-22 | |
| US201562247576P | 2015-10-28 | 2015-10-28 | |
| US201562248252P | 2015-10-29 | 2015-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018001056A1 true CL2018001056A1 (es) | 2018-10-19 |
Family
ID=58558127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018001056A CL2018001056A1 (es) | 2015-10-22 | 2018-04-20 | Vacuna contra el virus herpes simplex |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20180303929A1 (enExample) |
| EP (1) | EP3365009A4 (enExample) |
| JP (2) | JP2018536023A (enExample) |
| KR (1) | KR20180096593A (enExample) |
| CN (1) | CN108472355A (enExample) |
| AU (2) | AU2016342049B2 (enExample) |
| BR (1) | BR112018008090A2 (enExample) |
| CA (1) | CA3002822A1 (enExample) |
| CL (1) | CL2018001056A1 (enExample) |
| CO (1) | CO2018005258A2 (enExample) |
| EA (1) | EA201890999A1 (enExample) |
| IL (1) | IL258833A (enExample) |
| MA (1) | MA46024A (enExample) |
| MX (1) | MX2018004918A (enExample) |
| PE (1) | PE20181531A1 (enExample) |
| PH (1) | PH12018500855A1 (enExample) |
| SG (1) | SG11201803365RA (enExample) |
| TN (1) | TN2018000155A1 (enExample) |
| WO (1) | WO2017070623A1 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3134131T (pt) | 2014-04-23 | 2022-03-24 | Modernatx Inc | Vacinas de ácidos nucleicos |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| EP4218805A1 (en) | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Infectious disease vaccines |
| EP3328394A4 (en) | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | CONCATEMEE peptide epitope RNAs |
| WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| EP4349404A3 (en) | 2015-10-22 | 2024-06-19 | ModernaTX, Inc. | Respiratory virus vaccines |
| SG11201803360UA (en) | 2015-10-22 | 2018-05-30 | Modernatx Inc | Nucleic acid vaccines for varicella zoster virus (vzv) |
| CA3002922A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| MA45209A (fr) | 2015-10-22 | 2019-04-17 | Modernatx Inc | Vaccins contre les maladies sexuellement transmissibles |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
| EP3386484B1 (en) | 2015-12-10 | 2022-03-30 | ModernaTX, Inc. | Compositions and methods for delivery of therapeutic agents |
| US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
| MA45052A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille |
| IL263079B2 (en) | 2016-05-18 | 2024-05-01 | Modernatx Inc | Polynucleotides encoding relaxin |
| SG11201901941YA (en) | 2016-09-14 | 2019-04-29 | Modernatx Inc | High purity rna compositions and methods for preparation thereof |
| EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | HUMAN CYTOMEGALOVIRUS VACCINE |
| WO2018089851A2 (en) | 2016-11-11 | 2018-05-17 | Modernatx, Inc. | Influenza vaccine |
| WO2018107088A2 (en) | 2016-12-08 | 2018-06-14 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| EP3582790A4 (en) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
| US11752206B2 (en) * | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Respiratory syncytial virus vaccine |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| EP3595676A4 (en) | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | RNA VACCINES AGAINST ZOONOSES |
| US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| EP3615060A4 (en) * | 2017-04-26 | 2021-06-09 | Merck Sharp & Dohme Corp. | HSV ANTIGEN PEPTIDS AND HSV PROTEIN VACCINES |
| WO2018200737A1 (en) * | 2017-04-26 | 2018-11-01 | Modernatx, Inc. | Herpes simplex virus vaccine |
| EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
| CN118370812A (zh) * | 2017-08-17 | 2024-07-23 | 宾夕法尼亚大学理事会 | 编码单纯疱疹病毒糖蛋白的修饰mrna疫苗及其用途 |
| WO2019036685A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR HPLC ANALYSIS |
| WO2019036683A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | ANALYTICAL METHODS BY HPLC |
| CN111212905A (zh) | 2017-08-18 | 2020-05-29 | 摩登纳特斯有限公司 | Rna聚合酶变体 |
| CA3073211A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| EP3681514A4 (en) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | RNA VACZINE AGAINST ZIKA VIRUS |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| EP4509118A3 (en) | 2018-09-19 | 2025-05-14 | ModernaTX, Inc. | High-purity peg lipids and uses thereof |
| CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| CN109701008B (zh) * | 2019-02-18 | 2022-06-21 | 山东兴瑞生物科技有限公司 | 针对单纯疱疹病毒的治疗性dc复合疫苗及其制备方法 |
| MA55037A (fr) | 2019-02-20 | 2021-12-29 | Modernatx Inc | Variants d'arn polymérase pour le coiffage co-transcriptionnel |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| EP3938507A4 (en) | 2019-03-11 | 2023-02-22 | ModernaTX, Inc. | PROCEDURE FOR IN VITRO FED BATCH TRANSCRIPTION |
| MA55321A (fr) | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
| WO2021015987A1 (en) * | 2019-07-19 | 2021-01-28 | Merck Sharp & Dohme Corp. | Antigenic glycoprotein e polypeptides, compositions, and methods of use thereof |
| AU2020318680B2 (en) * | 2019-07-21 | 2025-04-24 | Glaxosmithkline Biologicals Sa | Therapeutic viral vaccine |
| WO2021197589A1 (en) * | 2020-03-31 | 2021-10-07 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination |
| EP3901261A1 (en) | 2020-04-22 | 2021-10-27 | BioNTech RNA Pharmaceuticals GmbH | Coronavirus vaccine |
| JP2023533721A (ja) | 2020-07-02 | 2023-08-04 | ライフ テクノロジーズ コーポレーション | トリヌクレオチドキャップ類似体、それらの調製、及び使用 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| CA3211277A1 (en) * | 2021-03-11 | 2022-09-15 | Marina TAMBASCO STUDART | Vaccine compositions and methods for treating hsv |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| IL309505A (en) | 2021-09-03 | 2024-02-01 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| EP4422698A1 (en) | 2021-10-29 | 2024-09-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US20250360194A1 (en) | 2021-12-08 | 2025-11-27 | Modernatx, Inc. | Herpes simplex virus mrna vaccines |
| US20250345416A1 (en) * | 2022-01-27 | 2025-11-13 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
| EP4469091A1 (en) | 2022-01-28 | 2024-12-04 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CA3248209A1 (en) | 2022-05-25 | 2023-11-30 | CureVac SE | Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH) |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| DE202023106198U1 (de) | 2022-10-28 | 2024-03-21 | CureVac SE | Impfstoff auf Nukleinsäurebasis |
| TW202440929A (zh) | 2022-12-14 | 2024-10-16 | 加拿大商普羅維登斯治療控股公司 | 用於感染性疾病的組合物和方法 |
| CN118217388A (zh) * | 2022-12-19 | 2024-06-21 | 南京奥罗生物科技有限公司 | 单纯疱疹病毒疫苗及其应用 |
| EP4658306A1 (en) | 2023-01-30 | 2025-12-10 | ModernaTX, Inc. | Epstein-barr virus mrna vaccines |
| DE112024001143T5 (de) | 2023-03-08 | 2025-12-18 | CureVac SE | Neue lipid-nanopartikel-formeln für die abgabe von nukleinsäuren |
| WO2024215721A1 (en) | 2023-04-10 | 2024-10-17 | Modernatx, Inc. | Lyme disease vaccines |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| WO2025030097A2 (en) * | 2023-08-03 | 2025-02-06 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
| WO2025171082A1 (en) * | 2024-02-06 | 2025-08-14 | Board Of Regents, The University Of Texas System | Prefusion-stabilized hsv2 gb proteins |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| WO1993001301A1 (en) * | 1991-07-05 | 1993-01-21 | The Penn State Research Foundation | Mutant antiviral regulatory proteins |
| GB9406498D0 (en) * | 1994-03-31 | 1994-05-25 | Smithkline Beecham Biolog | Novel compounds |
| US7094767B2 (en) * | 1994-07-22 | 2006-08-22 | Merck & Co., Inc. | Polynucleotide herpes virus vaccine |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| JP2001508649A (ja) * | 1996-11-04 | 2001-07-03 | スミスクライン・ビーチャム・コーポレイション | ２型単純ヘルペスウイルス由来の新規コーディング配列 |
| EP1222281B1 (en) * | 1999-09-30 | 2006-11-15 | University of Washington | Immunoligically significant herpes simplex virus antigens |
| MXPA02012198A (es) * | 2000-06-09 | 2004-08-19 | Teni Boulikas | Encapsulacion de polinucleotidos y drogas en liposomas objetivos. |
| US6998115B2 (en) | 2000-10-10 | 2006-02-14 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
| US7708915B2 (en) | 2004-05-06 | 2010-05-04 | Castor Trevor P | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein |
| EP1903054A3 (de) | 2001-06-05 | 2008-07-23 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie |
| EP1412065A2 (en) | 2001-07-27 | 2004-04-28 | President And Fellows Of Harvard College | Laminar mixing apparatus and methods |
| US20060051424A1 (en) | 2001-10-03 | 2006-03-09 | Johns Hopkins University | Compositions of oral gene therapy and methods of using same |
| AU2003217531A1 (en) | 2002-05-02 | 2003-11-17 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
| EP1691780A2 (en) * | 2003-11-21 | 2006-08-23 | Alza Corporation | Gene delivery mediated by liposome-dna complex with cleavable peg surface modification |
| EP1713514B1 (en) | 2004-01-28 | 2021-11-24 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
| WO2006097793A2 (en) | 2004-04-15 | 2006-09-21 | Chiasma, Ltd. | Compositions capable of facilitating penetration across a biological barrier |
| EP1856179B1 (en) | 2004-12-10 | 2013-05-15 | Kala Pharmaceuticals, Inc. | Functionalized poly (ether-anhydride) block copolymers |
| KR101288729B1 (ko) | 2005-04-01 | 2013-07-23 | 인터자인 테크놀로지스, 인코포레이티드 | 약물 전달용 중합체성 마이셀 |
| EP1885403B1 (en) | 2005-04-12 | 2013-05-08 | Nektar Therapeutics | Poly(ethyleneglycol) conjugates of Lysostaphin |
| CA2611823C (en) | 2005-06-16 | 2013-07-30 | Nektar Therapeutics Al, Corporation | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
| WO2007070705A2 (en) * | 2005-12-15 | 2007-06-21 | The Trustees Of The University Of Pennsylvania | Cationic lipid-mediated vectors |
| CA2642905C (en) | 2006-02-21 | 2015-04-28 | Nektar Therapeutics Al, Corporation | Segmented degradable polymers and conjugates made therefrom |
| CN101573141B (zh) | 2006-05-15 | 2016-05-04 | 麻省理工学院 | 用于功能性颗粒的聚合物 |
| NZ572808A (en) * | 2006-05-19 | 2011-11-25 | Water And Eliza Hall Inst Of Medical Res | Compositions for raising an immune response comprising an antigen and a targeting moiety for lymph-resident dendritic cells |
| CA2658484A1 (en) * | 2006-07-20 | 2008-01-24 | Vical Incorporated | Compositions and methods for vaccinating against hsv-2 |
| ATE498393T1 (de) | 2006-09-08 | 2011-03-15 | Univ Johns Hopkins | Zusammensetzungen zur transportintensivierung durch die schleimhaut |
| EP2120859B1 (en) | 2006-12-21 | 2013-11-20 | Stryker Corporation | Sustained-release formulations comprising bmp-7 crystals |
| US8877206B2 (en) * | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| ES2647538T3 (es) | 2007-09-28 | 2017-12-22 | Pfizer Inc. | Direccionamiento a células de cáncer usando nanopartículas |
| WO2010005740A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences, Inc. | Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles |
| WO2010005725A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
| PT2774608T (pt) | 2008-06-16 | 2020-01-17 | Pfizer | Nanopartículas poliméricas carregadas com fármaco e métodos de produção e utilização das mesmas |
| US8613951B2 (en) | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
| US20100087337A1 (en) | 2008-09-10 | 2010-04-08 | Bind Biosciences, Inc. | High Throughput Fabrication of Nanoparticles |
| WO2010075072A2 (en) | 2008-12-15 | 2010-07-01 | Bind Biosciences | Long circulating nanoparticles for sustained release of therapeutic agents |
| JP5622254B2 (ja) | 2009-03-31 | 2014-11-12 | 国立大学法人東京大学 | 二本鎖リボ核酸ポリイオンコンプレックス |
| US8287910B2 (en) | 2009-04-30 | 2012-10-16 | Intezyne Technologies, Inc. | Polymeric micelles for polynucleotide encapsulation |
| CN107028886A (zh) | 2009-11-04 | 2017-08-11 | 不列颠哥伦比亚大学 | 含有核酸的脂质粒子及相关的方法 |
| JP6175237B2 (ja) | 2009-12-15 | 2017-08-02 | ファイザー・インク | コルチコステロイドを含む治療用ポリマーナノ粒およびそれを製造かつ使用する方法 |
| JP5898627B2 (ja) | 2009-12-15 | 2016-04-06 | バインド セラピューティックス インコーポレイテッド | エポチロンを含む治療用ポリマーナノ粒子ならびにそれを製造および使用する方法 |
| US9295649B2 (en) | 2009-12-15 | 2016-03-29 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
| CA2787598A1 (en) | 2010-01-24 | 2012-06-21 | Novartis Ag | Irradiated biodegradable polymer microparticles |
| WO2011106607A2 (en) * | 2010-02-26 | 2011-09-01 | Juvaris Biotherapeutics, Inc. | Subunit vaccines for herpes viruses and methods of use |
| WO2011119262A1 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Methods and systems for generating nanoparticles |
| US20110262491A1 (en) | 2010-04-12 | 2011-10-27 | Selecta Biosciences, Inc. | Emulsions and methods of making nanocarriers |
| EP2575895A2 (en) | 2010-05-24 | 2013-04-10 | Merck Sharp & Dohme Corp. | Novel amino alcohol cationic lipids for oligonucleotide delivery |
| US20130196948A1 (en) | 2010-06-25 | 2013-08-01 | Massachusetts Insitute Of Technology | Polymers for biomaterials and therapeutics |
| RS63817B1 (sr) * | 2010-07-06 | 2023-01-31 | Glaxosmithkline Biologicals Sa | Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk |
| US10307372B2 (en) | 2010-09-10 | 2019-06-04 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| ES2945135T3 (es) * | 2010-10-11 | 2023-06-28 | Glaxosmithkline Biologicals Sa | Plataformas de suministro de antígenos |
| US20150056300A1 (en) | 2010-10-22 | 2015-02-26 | Bind Therapeutics, Inc. | Therapeutic nanoparticles with high molecular weight copolymers |
| US20120121718A1 (en) | 2010-11-05 | 2012-05-17 | The Johns Hopkins University | Compositions and methods relating to reduced mucoadhesion |
| WO2012099805A2 (en) | 2011-01-19 | 2012-07-26 | Ocean Nanotech, Llc | Nanoparticle based immunological stimulation |
| CN107090463A (zh) * | 2011-01-31 | 2017-08-25 | 宾夕法尼亚大学托管会 | 编码新型疱疹抗原的核酸分子、包含所述核酸分子的疫苗及其使用方法 |
| WO2012109121A1 (en) | 2011-02-07 | 2012-08-16 | Purdue Research Foundation | Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide |
| US9901554B2 (en) | 2011-03-31 | 2018-02-27 | Ingell Technologies Holding B.V. | Biodegradable compositions suitable for controlled release |
| CA2831471C (en) | 2011-03-31 | 2020-02-25 | Ingell Technologies Holding B.V. | Biodegradable compositions suitable for controlled release |
| US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| WO2012166923A2 (en) | 2011-05-31 | 2012-12-06 | Bind Biosciences | Drug loaded polymeric nanoparticles and methods of making and using same |
| ES2861428T3 (es) * | 2011-07-06 | 2021-10-06 | Glaxosmithkline Biologicals Sa | Liposomas que presentan una relación N:P útil para suministro de moléculas de ARN |
| BR112014001050B1 (pt) | 2011-07-21 | 2017-12-05 | Croda International Plc | Polyester polyester block polymer, method for the preparation of the same, composition, controlled release and personal care products, and method for preparing a gel composition |
| CA2842039A1 (en) | 2011-08-26 | 2013-03-07 | Arrowhead Research Corporation | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
| CN103930135A (zh) | 2011-08-31 | 2014-07-16 | 马林克罗特有限公司 | 使用h-膦酸酯的纳米颗粒peg修饰 |
| US20150017245A1 (en) | 2011-09-22 | 2015-01-15 | Bind Therapeutics, Inc. | Methods of treating cancers with therapeutic nanoparticles |
| WO2013072929A2 (en) | 2011-09-23 | 2013-05-23 | Indian Institute Of Technology | Nanop article based cosmetic composition |
| CN104105504A (zh) * | 2011-10-11 | 2014-10-15 | 诺华股份有限公司 | 重组多顺反子核酸分子 |
| CN103987847B (zh) | 2011-10-18 | 2017-06-16 | 迪克纳制药公司 | 胺阳离子脂质及其用途 |
| AU2012328570B2 (en) | 2011-10-27 | 2017-08-31 | Massachusetts Institute Of Technology | Amino acid derivatives functionalized on the n-terminus capable of forming drug encapsulating microspheres and uses thereof |
| WO2013078199A2 (en) | 2011-11-23 | 2013-05-30 | Children's Medical Center Corporation | Methods for enhanced in vivo delivery of synthetic, modified rnas |
| MX2014007233A (es) * | 2011-12-16 | 2015-02-04 | Moderna Therapeutics Inc | Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados. |
| RU2598627C2 (ru) | 2012-01-19 | 2016-09-27 | Дзе Джонс Хопкинс Юниверсити | Композиции на основе наночастиц с улучшенным проникновением через слизистые оболочки |
| WO2013113326A1 (en) * | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| WO2013116804A2 (en) | 2012-02-03 | 2013-08-08 | Rutgers, The State Of University Of New Jersey | Polymeric biomaterials derived from phenolic monomers and their medical uses |
| WO2013120052A1 (en) | 2012-02-10 | 2013-08-15 | E. I. Du Pont De Nemours And Company | Preparation, purification and use of high-x diblock copolymers |
| WO2013143555A1 (en) * | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| WO2013151663A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| EP3884949A1 (en) * | 2012-06-08 | 2021-09-29 | Translate Bio, Inc. | Pulmonary delivery of mrna to non-lung target cells |
| ES2968649T3 (es) * | 2012-12-07 | 2024-05-13 | Translate Bio Inc | Nanopartículas lipídicas para la administración de ARNm en los pulmones |
| EP2931319B1 (en) * | 2012-12-13 | 2019-08-21 | ModernaTX, Inc. | Modified nucleic acid molecules and uses thereof |
| BR112015022855A2 (pt) * | 2013-03-14 | 2017-11-07 | Shire Human Genetic Therapies | composições e método para produção de um anticorpo in vitro |
| WO2014144767A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
| EP2971161B1 (en) | 2013-03-15 | 2018-12-26 | ModernaTX, Inc. | Ribonucleic acid purification |
| WO2014152027A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
| RS57316B1 (sr) * | 2013-03-15 | 2018-08-31 | Translate Bio Inc | Sinergističko poboljšanje isporuke nukleinskih kiselina pomoću mešavina formulacija |
| US20160017313A1 (en) | 2013-03-15 | 2016-01-21 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
| WO2014144039A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
| US10077439B2 (en) | 2013-03-15 | 2018-09-18 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
| TW201534578A (zh) * | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | 新穎脂質 |
| PT3134131T (pt) * | 2014-04-23 | 2022-03-24 | Modernatx Inc | Vacinas de ácidos nucleicos |
| WO2018226638A1 (en) * | 2017-06-05 | 2018-12-13 | The Brigham And Women's Hospital, Inc. | Vero cell lines stably expressing hsv icp0 protein |
-
2016
- 2016-10-21 KR KR1020187014340A patent/KR20180096593A/ko not_active Withdrawn
- 2016-10-21 JP JP2018541090A patent/JP2018536023A/ja active Pending
- 2016-10-21 EA EA201890999A patent/EA201890999A1/ru unknown
- 2016-10-21 AU AU2016342049A patent/AU2016342049B2/en not_active Ceased
- 2016-10-21 BR BR112018008090A patent/BR112018008090A2/pt not_active Application Discontinuation
- 2016-10-21 CN CN201680075061.1A patent/CN108472355A/zh active Pending
- 2016-10-21 CA CA3002822A patent/CA3002822A1/en active Pending
- 2016-10-21 SG SG11201803365RA patent/SG11201803365RA/en unknown
- 2016-10-21 MX MX2018004918A patent/MX2018004918A/es unknown
- 2016-10-21 EP EP16858403.5A patent/EP3365009A4/en active Pending
- 2016-10-21 US US15/767,618 patent/US20180303929A1/en not_active Abandoned
- 2016-10-21 WO PCT/US2016/058322 patent/WO2017070623A1/en not_active Ceased
- 2016-10-21 TN TNP/2018/000155A patent/TN2018000155A1/en unknown
- 2016-10-21 PE PE2018000600A patent/PE20181531A1/es unknown
- 2016-10-21 MA MA046024A patent/MA46024A/fr unknown
-
2018
- 2018-04-20 CL CL2018001056A patent/CL2018001056A1/es unknown
- 2018-04-20 PH PH12018500855A patent/PH12018500855A1/en unknown
- 2018-04-22 IL IL258833A patent/IL258833A/en unknown
- 2018-05-21 CO CONC2018/0005258A patent/CO2018005258A2/es unknown
-
2021
- 2021-12-16 JP JP2021204272A patent/JP2022037134A/ja active Pending
-
2023
- 2023-08-17 AU AU2023216825A patent/AU2023216825A1/en not_active Abandoned
- 2023-10-04 US US18/481,204 patent/US20240173400A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3002822A1 (en) | 2017-04-27 |
| JP2018536023A (ja) | 2018-12-06 |
| TN2018000155A1 (en) | 2019-10-04 |
| US20240173400A1 (en) | 2024-05-30 |
| EP3365009A1 (en) | 2018-08-29 |
| CO2018005258A2 (es) | 2018-11-22 |
| BR112018008090A2 (pt) | 2018-11-13 |
| EA201890999A1 (ru) | 2018-12-28 |
| JP2022037134A (ja) | 2022-03-08 |
| EP3365009A4 (en) | 2019-07-03 |
| SG11201803365RA (en) | 2018-05-30 |
| MA46024A (fr) | 2019-07-03 |
| CN108472355A (zh) | 2018-08-31 |
| AU2016342049A1 (en) | 2018-06-07 |
| AU2016342049B2 (en) | 2023-05-18 |
| PH12018500855A1 (en) | 2018-10-29 |
| US20180303929A1 (en) | 2018-10-25 |
| WO2017070623A1 (en) | 2017-04-27 |
| KR20180096593A (ko) | 2018-08-29 |
| PE20181531A1 (es) | 2018-09-26 |
| AU2023216825A1 (en) | 2023-09-07 |
| IL258833A (en) | 2018-06-28 |
| MX2018004918A (es) | 2019-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018001056A1 (es) | Vacuna contra el virus herpes simplex | |
| CL2018001053A1 (es) | Vacuna contra el virus sincicial respiratorio | |
| CY1125368T1 (el) | Εμβολια κατα των ιων του αναπνευστικου συστηματος | |
| BR112018008078A2 (pt) | vacina de vírus influenza de amplo espectro | |
| CO2017011535A2 (es) | Composiciones de ácido obeticólico y métodos de uso | |
| MX2018012880A (es) | Metodos para proporcionar arn de hebra sencilla. | |
| MX390064B (es) | Formas cristalinas de mononucleotido de beta-nicotinamida. | |
| BR112016024644A2 (pt) | vacinas de ácido nucleico | |
| CO2017002253A2 (es) | Compuesto dirigido a il-23a y tnf-alfa | |
| DOP2022000085A (es) | Composiciones y métodos para inhibir la expresión del gen alas1 | |
| BR112016018654A2 (pt) | Composições de silicato estabilizadas e seu uso como composições antiperspirantes | |
| MX2021010060A (es) | Produccion de virus en huevos aviares. | |
| MX2021000773A (es) | Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo. | |
| BR112017003462A2 (pt) | coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino. | |
| MX381252B (es) | Virus de la enteritis del pato y usos del mismo. | |
| CO2018010359A2 (es) | Constructos de alfavirus vivo atenuado y métodos y usos de los mismos | |
| MX382530B (es) | Vacunas inactivadas contra la influenza canina, metodos para elaborarlas y sus usos. | |
| MX2018009370A (es) | Regulacion de expresion genica a través de poliadenilacion modulada por aptámeros. | |
| PE20160596A1 (es) | Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana | |
| TR201819130T4 (tr) | Sulu Formülasyonlar, Bunların Üretimi Ve Kullanımı | |
| AR106464A1 (es) | Vacuna de virus sincitial respiratorio | |
| BR112017027132A2 (pt) | reguladores do nrf2 | |
| MX2024007379A (es) | Vacunas para el virus del papiloma humano y metodos para su uso. |